This is an old revision of the document!
Eli Lilly
Eli Lilly is an American pharmaceutical company based in Indianapolis, Indiana.
Portfolio
Eli Lilly has an exclusive worldwide licensing agreement with Centrexion Therapeutics for CNTX-0290, a novel, small molecule somatostatin receptor type 4 (SSTR4) agonist. At the time of the deal, it was in clinical trials as a potential non-opioid treatment for chronic pain conditions.1)
COVID-19
Eli Lilly has Emergency Use Authorization from the U.S. Food and Drug Administration for three experimental COVID-19 drugs: Bamlanivimab, Etesevimab and Olumiant (in combination with remdesivir).2) 3)
Eli Lilly partnered with Amgen to manufacture their COVID-19 antibody therapy products.4) Eli Lilly is also part of the COVID-19 Therapeutics Accelerator funded by the Bill & Melinda Gates Foundation, Wellcome Trust, and Mastercard to “accelerate treatments, vaccines, and diagnostics”.
1)
Taylor, M., Hern, K., Normart, J., & Dugan, C. (2019, May 28). Lilly Announces Licensing Agreement for Non-Opioid Pain Asset from Centrexion Therapeutics. Eli Lilly. https://investor.lilly.com/news-releases/news-release-details/lilly-announces-licensing-agreement-non-opioid-pain-asset
2)
O’Shaughnessy, J. A., PhD. (2021, December 3). RE: Emergency Use Authorization 094. Eli Lilly. Retrieved December 6, 2021, from
http://pi.lilly.com/eua/bam-and-ete-eua-fda-authorization-letter.pdf
3)
Hinton, D. M. (2021, July 28). Baricitinib EUA FDA Authorization Letter. Eli Lilly. Retrieved December 6, 2021, from
http://pi.lilly.com/eua/baricitinib-eua-fda-authorization-letter.pdf
4)
Taylor, M., & Rowland, T. (2020, September 17). Lilly and Amgen Announce Manufacturing Collaboration for COVID-19 Antibody Therapies. Amgen. https://archive.ph/pXXV5